Karolinska Institutet
Browse

Helicobacter pylori eradication in the Swedish population.

Download (376.8 kB)
journal contribution
posted on 2024-10-25, 11:41 authored by Eva Doorakkers, Jesper LagergrenJesper Lagergren, Vijaya Krishna GajulapuriVijaya Krishna Gajulapuri, Steven Callens, Lars EngstrandLars Engstrand, Nele BrusselaersNele Brusselaers
OBJECTIVES: Helicobacter pylori is associated with peptic ulcers and gastric cancer and its eradication aims to prevent these conditions. The recommended eradication regimen is triple therapy, consisting of a proton-pump inhibitor in combination with clarithromycin and amoxicillin or metronidazole for 7 days. Yet, other antibiotic regimens are sometimes prescribed. We aimed to assess the use of eradication therapy for H. pylori in the Swedish population during the last decade. MATERIALS AND METHODS: This population-based study used data from the Swedish Prescribed Drug Register. From July 2005 until December 2014, all regimens that can eradicate H. pylori were identified and evaluated according to patients' age and sex and calendar year of eradication. RESULTS: We identified 157,915 eradication episodes in 140,391 individuals (53.8% women, 42.6% older than 60 years), who correspond to 1.5% of the Swedish population. The absolute number and incidence of eradications decreased over the study period. Overall, 91.0% had one eradication and 0.1% had more than three. Of all eradications, 95.4% followed the recommended regimen, while 4.7% did not. The latter group was overrepresented among individuals aged ≥80 years (7.8%). Amoxicillin and clarithromycin were most frequently prescribed, while metronidazole was rarely used (0.01%). Other prescribed antibiotics were ciprofloxacin (2.4%), doxycycline (1.4%), nitrofurantoin (0.7%), norfloxacin (0.5%) and erythromycin (0.3%). CONCLUSIONS: During the last decade in Sweden H. pylori eradication has been frequently prescribed, but the incidence of eradication has slowly declined. Most eradications followed the recommended regimen, including those occurring after a previous eradication.

Funding

Novel opportunities for improved prevention, detection and therapy of oesophageal adenocarcinoma : Swedish Research Council | 2014-02536_VR

History

File version

  • Accepted manuscript

Publication status

Published

Sub type

Article

Journal

Scand J Gastroenterol

ISSN

0036-5521

eISSN

1502-7708

Volume

52

Issue

6-7

Pagination

678-685

Language

  • eng

Handle

10616/45912

Original self archiving date

2017-04-28

Usage metrics

    Articles

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC